1
|
Kohn T, Dumas K, Kohn J, Agrawal P, Clifton M. Characteristics of Systemic Testosterone Therapy for Female Hypoactive Sexual Desire Disorder – A Claims Database Analysis. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.05.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
2
|
Dumas K, Kohn J, Kohn T, Clifton M. Rate of Prior Invasive Pelvic Procedures, Co-Diagnoses, and Treatment Choices in Women Presenting with Dyspareunia – A United States Claims Database Analysis. J Sex Med 2022. [DOI: 10.1016/j.jsxm.2022.05.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
3
|
Cougnon M, Carcy R, Melis N, Rubera I, Duranton C, Dumas K, Tanti JF, Pons C, Soubeiran N, Shkreli M, Hauet T, Pellerin L, Giraud S, Blondeau N, Tauc M, Pisani DF. Inhibition of eIF5A hypusination reprogrammes metabolism and glucose handling in mouse kidney. Cell Death Dis 2021; 12:283. [PMID: 33731685 PMCID: PMC7969969 DOI: 10.1038/s41419-021-03577-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2020] [Revised: 02/24/2021] [Accepted: 03/01/2021] [Indexed: 12/13/2022]
Abstract
Inhibition of the eukaryotic initiation factor 5A activation by the spermidine analogue GC7 has been shown to protect proximal cells and whole kidneys against an acute episode of ischaemia. The highlighted mechanism involves a metabolic switch from oxidative phosphorylation toward glycolysis allowing cells to be transiently independent of oxygen supply. Here we show that GC7 decreases protein expression of the renal GLUT1 glucose transporter leading to a decrease in transcellular glucose flux. At the same time, GC7 modifies the native energy source of the proximal cells from glutamine toward glucose use. Thus, GC7 acutely and reversibly reprogrammes function and metabolism of kidney cells to make glucose its single substrate, and thus allowing cells to be oxygen independent through anaerobic glycolysis. The physiological consequences are an increase in the renal excretion of glucose and lactate reflecting a decrease in glucose reabsorption and an increased glycolysis. Such a reversible reprogramming of glucose handling and oxygen dependence of kidney cells by GC7 represents a pharmacological opportunity in ischaemic as well as hyperglycaemia-associated pathologies from renal origin.
Collapse
Affiliation(s)
- Marc Cougnon
- Université Côte d'Azur, CNRS, LP2M, Nice, France
| | - Romain Carcy
- CHU Nice, Hôpital Pasteur 2, Service de Réanimation Polyvalente et Service de Réanimation des Urgences Vitales, Nice, France
| | - Nicolas Melis
- Université Côte d'Azur, CNRS, LP2M, Nice, France
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892, USA
| | | | | | - Karine Dumas
- Université Côte d'Azur, INSERM, C3M, Nice, France
| | | | - Catherine Pons
- Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France
| | | | - Marina Shkreli
- Université Côte d'Azur, CNRS, INSERM, IRCAN, Nice, France
| | - Thierry Hauet
- Université de Poitiers, INSERM, IRTOMIT, CHU de Poitiers, La Milétrie, Poitiers, France
| | - Luc Pellerin
- Université de Poitiers, INSERM, IRTOMIT, CHU de Poitiers, La Milétrie, Poitiers, France
| | | | | | - Michel Tauc
- Université Côte d'Azur, CNRS, LP2M, Nice, France.
| | | |
Collapse
|
4
|
Britto FA, Dumas K, Giorgetti-Peraldi S, Ollendorff V, Favier FB. Is REDD1 a metabolic double agent? Lessons from physiology and pathology. Am J Physiol Cell Physiol 2020; 319:C807-C824. [PMID: 32877205 DOI: 10.1152/ajpcell.00340.2020] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The Akt/mechanistic target of rapamycin (mTOR) signaling pathway governs macromolecule synthesis, cell growth, and metabolism in response to nutrients and growth factors. Regulated in development and DNA damage response (REDD)1 is a conserved and ubiquitous protein, which is transiently induced in response to multiple stimuli. Acting like an endogenous inhibitor of the Akt/mTOR signaling pathway, REDD1 protein has been shown to regulate cell growth, mitochondrial function, oxidative stress, and apoptosis. Recent studies also indicate that timely REDD1 expression limits Akt/mTOR-dependent synthesis processes to spare energy during metabolic stresses, avoiding energy collapse and detrimental consequences. In contrast to this beneficial role for metabolic adaptation, REDD1 chronic expression appears involved in the pathogenesis of several diseases. Indeed, REDD1 expression is found as an early biomarker in many pathologies including inflammatory diseases, cancer, neurodegenerative disorders, depression, diabetes, and obesity. Moreover, prolonged REDD1 expression is associated with cell apoptosis, excessive reactive oxygen species (ROS) production, and inflammation activation leading to tissue damage. In this review, we decipher several mechanisms that make REDD1 a likely metabolic double agent depending on its duration of expression in different physiological and pathological contexts. We also discuss the role played by REDD1 in the cross talk between the Akt/mTOR signaling pathway and the energetic metabolism.
Collapse
Affiliation(s)
| | - Karine Dumas
- Université Cote d'Azur, INSERM, UMR1065, C3M, Nice, France
| | | | | | | |
Collapse
|
5
|
Dumas K, Ayachi C, Gilleron J, Lacas‐Gervais S, Pastor F, Favier FB, Peraldi P, Vaillant N, Yvan‐Charvet L, Bonnafous S, Patouraux S, Anty R, Tran A, Gual P, Cormont M, Tanti J, Giorgetti‐Peraldi S. REDD1 deficiency protects against nonalcoholic hepatic steatosis induced by high‐fat diet. FASEB J 2020; 34:5046-5060. [DOI: 10.1096/fj.201901799rr] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2019] [Revised: 01/24/2020] [Accepted: 01/24/2020] [Indexed: 12/11/2022]
Affiliation(s)
- Karine Dumas
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| | - Chaima Ayachi
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| | - Jerome Gilleron
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| | | | - Faustine Pastor
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| | | | - Pascal Peraldi
- Université Côte d’Azur, Inserm, CNRS, iBV, Team “Stem Cells and Differentiation” France
| | - Nathalie Vaillant
- Université Côte d’Azur, Inserm, C3M, Team “Haematometabolism in Diseases” France
| | - Laurent Yvan‐Charvet
- Université Côte d’Azur, Inserm, C3M, Team “Haematometabolism in Diseases” France
| | - Stéphanie Bonnafous
- Université Côte d’Azur, Inserm, C3M, Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
- Université Côte d’Azur, CHU, Inserm, C3M,Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
| | - Stéphanie Patouraux
- Université Côte d’Azur, Inserm, C3M, Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
- Université Côte d’Azur, CHU, Inserm, C3M,Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
| | - Rodolphe Anty
- Université Côte d’Azur, Inserm, C3M, Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
- Université Côte d’Azur, CHU, Inserm, C3M,Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
| | - Albert Tran
- Université Côte d’Azur, Inserm, C3M, Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
- Université Côte d’Azur, CHU, Inserm, C3M,Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
| | - Philippe Gual
- Université Côte d’Azur, Inserm, C3M, Team “Chronic Liver Diseases Associated with Steatosis and Alcohol” France
| | - Mireille Cormont
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| | - Jean‐François Tanti
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| | - Sophie Giorgetti‐Peraldi
- Université Côte d’Azur, Inserm, C3M, Team “Cellular and Molecular Physiopathology of Obesity” France
| |
Collapse
|
6
|
Gilleron J, Bouget G, Ivanov S, Meziat C, Ceppo F, Vergoni B, Djedaini M, Soprani A, Dumas K, Jacquel A, Yvan-Charvet L, Venteclef N, Tanti JF, Cormont M. Rab4b Deficiency in T Cells Promotes Adipose Treg/Th17 Imbalance, Adipose Tissue Dysfunction, and Insulin Resistance. Cell Rep 2019; 25:3329-3341.e5. [PMID: 30566860 DOI: 10.1016/j.celrep.2018.11.083] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Revised: 09/04/2018] [Accepted: 11/21/2018] [Indexed: 12/18/2022] Open
Abstract
Obesity modifies T cell populations in adipose tissue, thereby contributing to adipose tissue inflammation and insulin resistance. Here, we show that Rab4b, a small GTPase governing endocytic trafficking, is pivotal in T cells for the development of these pathological events. Rab4b expression is decreased in adipose T cells from mice and patients with obesity. The specific depletion of Rab4b in T cells causes adipocyte hypertrophy and insulin resistance in chow-fed mice and worsens insulin resistance in obese mice. This phenotype is driven by an increase in adipose Th17 and a decrease in adipose Treg due to a cell-autonomous skew of differentiation toward Th17. The Th17/Treg imbalance initiates adipose tissue inflammation and reduces adipogenesis, leading to lipid deposition in liver and muscles. Therefore, we propose that the obesity-induced loss of Rab4b in adipose T cells may contribute to maladaptive white adipose tissue remodeling and insulin resistance by altering adipose T cell fate.
Collapse
Affiliation(s)
- Jérôme Gilleron
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Gwennaëlle Bouget
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Stoyan Ivanov
- Université Côte d'Azur, Nice, France; INSERM U1065, Centre Méditerranéen de Médecine Moléculaire C3M, Team "Metabolism and Cancer," Nice, France
| | - Cindy Meziat
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Franck Ceppo
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Bastien Vergoni
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Mansour Djedaini
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Antoine Soprani
- Sorbonne Université, Université Pierre et Marie Curie, INSERM, UMR S_1138 Cordeliers Research Center, Paris, France; Clinique Geoffroy Saint-Hilaire, Ramsey Générale de Santé, Paris, France
| | - Karine Dumas
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Arnaud Jacquel
- Université Côte d'Azur, Nice, France; INSERM U1065, Centre Méditerranéen de Médecine Moléculaire C3M, Team "Cell Death, Differentiation, and Cancer," Nice, France
| | - Laurent Yvan-Charvet
- Université Côte d'Azur, Nice, France; INSERM U1065, Centre Méditerranéen de Médecine Moléculaire C3M, Team "Metabolism and Cancer," Nice, France
| | - Nicolas Venteclef
- Sorbonne Université, Université Pierre et Marie Curie, INSERM, UMR S_1138 Cordeliers Research Center, Paris, France
| | - Jean-François Tanti
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France
| | - Mireille Cormont
- INSERM UMR1065, Mediterranean Center of Molecular Medicine C3M, Team "Cellular and Molecular Physiopathology of Obesity and Diabetes," Nice, France; Université Côte d'Azur, Nice, France.
| |
Collapse
|
7
|
Saint-Laurent C, Garcia S, Sarrazy V, Dumas K, Authier F, Sore S, Tran A, Gual P, Gennero I, Salles JP, Gouze E. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia. PLoS One 2018; 13:e0195876. [PMID: 29652901 PMCID: PMC5898762 DOI: 10.1371/journal.pone.0195876] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Accepted: 03/30/2018] [Indexed: 12/12/2022] Open
Abstract
Background Achondroplasia is a rare genetic disease is characterized by abnormal bone development and early obesity. While the bone aspect of the disease has been thoroughly studied, early obesity affecting approximately 50% of them during childhood has been somewhat neglected. It nevertheless represents a major health problem in these patients, and is associated to life-threatening complications including increasing risk of cardiovascular pathologies. We have thus decided to study obesity in patients and to use the mouse model to evaluate if soluble FGFR3 therapy, an innovative treatment approach for achondroplasia, could also impact the development of this significant complication. Methods and findings To achieve this, we have first fully characterized the metabolic deregulations in these patients by conducting a longitudinal retrospective study, in children with achondroplasia Anthropometric, densitometric measures as well as several blood parameters were recorded and compared between three age groups ranging from [0–3], [4–8] and [9–18] years old. Our results show unexpected results with the development of an atypical obesity with preferential fat deposition in the abdomen that is remarkably not associated with classical complications of obesity such as diabetes or hypercholosterolemia. Because it is not associated with diabetes, the atypical obesity has not been studied in the past even though it is recognized as a real problem in these patients. These results were validated in a murine model of achondroplasia (Fgfr3ach/+) where similar visceral adiposity was observed. Unexpected alterations in glucose metabolism were highlighted during high-fat diet. Glucose, insulin or lipid levels remained low, without the development of diabetes. Very interestingly, in achondroplasia mice treated with soluble FGFR3 during the growth period (from D3 to D22), the development of these metabolic deregulations was prevented in adult animals (between 4 and 14 weeks of age). The lean-over-fat tissues ratio was restored and glucose metabolism showed normal levels. Treating Fgfr3ach/+ mice with soluble FGFR3 during the growth period, prevented the development of these metabolic deregulations in adult animals and restored lean-over-fat tissues ratio as well as glucose metabolism in adult animals. Conclusion This study demonstrate that achondroplasia patients develop an atypical obesity with preferential abdominal obesity not associated with classical complications. These results suggest that achondroplasia induces an uncommon metabolism of energy, directly linked to the FGFR3 mutation. These data strongly suggest that this common complication of achondroplasia should be included in the clinical management of patients. In this context, sFGFR3 proved to be a promising treatment for achondroplasia by normalizing the biology at different levels, not only restoring bone growth but also preventing the atypical visceral obesity and some metabolic deregulations.
Collapse
Affiliation(s)
- Celine Saint-Laurent
- Université Côte d’Azur, CNRS, Inserm, iBV, Nice, France
- Université Côte d’Azur, CHU, Inserm, C3M, Nice, France
| | | | | | - Karine Dumas
- Université Côte d’Azur, CHU, Inserm, C3M, Nice, France
| | | | - Sophie Sore
- Université Côte d’Azur, CNRS, Inserm, iBV, Nice, France
| | - Albert Tran
- Université Côte d’Azur, CHU, Inserm, C3M, Nice, France
| | - Philippe Gual
- Université Côte d’Azur, CHU, Inserm, C3M, Nice, France
| | - Isabelle Gennero
- University of Paul Sabatier Toulouse III, Inserm, CPTP, Toulouse, France
- Biochemistry Laboratory, Institut Federatif de Biologie, Toulouse University hospital, Toulouse, France
| | - Jean-Pierre Salles
- University of Paul Sabatier Toulouse III, Inserm, CPTP, Toulouse, France
- Endocrine, Bone Diseases, and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France
| | - Elvire Gouze
- Université Côte d’Azur, CNRS, Inserm, iBV, Nice, France
- Université Côte d’Azur, CHU, Inserm, C3M, Nice, France
- * E-mail:
| |
Collapse
|
8
|
Pastor F, Dumas K, Barthélémy MA, Regazzetti C, Druelle N, Peraldi P, Cormont M, Tanti JF, Giorgetti-Peraldi S. Implication of REDD1 in the activation of inflammatory pathways. Sci Rep 2017; 7:7023. [PMID: 28765650 PMCID: PMC5539207 DOI: 10.1038/s41598-017-07182-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2017] [Accepted: 06/26/2017] [Indexed: 01/14/2023] Open
Abstract
In response to endotoxemia, the organism triggers an inflammatory response, and the visceral adipose tissue represents a major source of proinflammatory cytokines. The regulation of inflammation response in the adipose tissue is thus of crucial importance. We demonstrated that Regulated in development and DNA damage response-1 (REDD1) is involved in inflammation. REDD1 expression was increased in response to lipopolysaccharide (LPS) in bone marrow derived macrophages (BMDM) and in epidydimal adipose tissue. Loss of REDD1 protected the development of inflammation, since the expression of proinflammatory cytokines (TNFα, IL-6, IL-1β) was decreased in adipose tissue of REDD1−/− mice injected with LPS compared to wild-type mice. This decrease was associated with an inhibition of the activation of p38MAPK, JNK, NF-κB and NLRP3 inflammasome leading to a reduction of IL-1β secretion in response to LPS and ATP in REDD1−/− BMDM. Although REDD1 is an inhibitor of mTORC1, loss of REDD1 decreased inflammation independently of mTORC1 activation but more likely through oxidative stress regulation. Absence of REDD1 decreases ROS associated with a dysregulation of Nox-1 and GPx3 expression. Absence of REDD1 in macrophages decreases the development of insulin resistance in adipocyte-macrophage coculture. Altogether, REDD1 appears to be a key player in the control of inflammation.
Collapse
Affiliation(s)
- Faustine Pastor
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France
| | - Karine Dumas
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France
| | - Marie-Astrid Barthélémy
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France
| | - Claire Regazzetti
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France.,Université Nice Côte d'Azur, Inserm U1065, C3M, Team " Study of the melanocytic differentiation applied to vitiligo and melanoma: from the patient to the molecular mechanisms", Nice, France
| | - Noémie Druelle
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France.,Université Nice Côte d'Azur, Inserm U1091, CNRS U7277, iBV, Team Diabetes genetic team, Nice, France
| | - Pascal Peraldi
- Université Nice Côte d'Azur, Inserm U1091, CNRS U7277, iBV, Team "Stem cells and differentiation", Nice, France
| | - Mireille Cormont
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France
| | - Jean-François Tanti
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France
| | - Sophie Giorgetti-Peraldi
- Université Nice Côte d'Azur, Inserm U1065, C3M, Team Cellular and Molecular Physiopathology of Obesity, Nice, France.
| |
Collapse
|
9
|
Berthou F, Ceppo F, Dumas K, Massa F, Vergoni B, Alemany S, Cormont M, Tanti JF. The Tpl2 Kinase Regulates the COX-2/Prostaglandin E2 Axis in Adipocytes in Inflammatory Conditions. Mol Endocrinol 2015; 29:1025-36. [PMID: 26020725 DOI: 10.1210/me.2015-1027] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Bioactive lipid mediators such as prostaglandin E2 (PGE2) have emerged as potent regulator of obese adipocyte inflammation and functions. PGE2 is produced by cyclooxygenases (COXs) from arachidonic acid, but inflammatory signaling pathways controlling COX-2 expression and PGE2 production in adipocytes remain ill-defined. Here, we demonstrated that the MAP kinase kinase kinase tumor progression locus 2 (Tpl2) controls COX-2 expression and PGE2 secretion in adipocytes in response to different inflammatory mediators. We found that pharmacological- or small interfering RNA-mediated Tpl2 inhibition in 3T3-L1 adipocytes decreased by 50% COX-2 induction in response to IL-1β, TNF-α, or a mix of the 2 cytokines. PGE2 secretion induced by the cytokine mix was also markedly blunted. At the molecular level, nuclear factor κB was required for Tpl2-induced COX-2 expression in response to IL-1β but was inhibitory for the TNF-α or cytokine mix response. In a coculture between adipocytes and macrophages, COX-2 was mainly increased in adipocytes and pharmacological inhibition of Tpl2 or its silencing in adipocytes markedly reduced COX-2 expression and PGE2 secretion. Further, Tpl2 inhibition in adipocytes reduces by 60% COX-2 expression induced by a conditioned medium from lipopolysaccharide (LPS)-treated macrophages. Importantly, LPS was less efficient to induce COX-2 mRNA in adipose tissue explants of Tpl2 null mice compared with wild-type and Tpl2 null mice displayed low COX-2 mRNA induction in adipose tissue in response to LPS injection. Collectively, these data established that activation of Tpl2 by inflammatory stimuli in adipocytes and adipose tissue contributes to increase COX-2 expression and production of PGE2 that could participate in the modulation of adipose tissue inflammation during obesity.
Collapse
Affiliation(s)
- Flavien Berthou
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Franck Ceppo
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Karine Dumas
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Fabienne Massa
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Bastien Vergoni
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Susana Alemany
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Mireille Cormont
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| | - Jean-François Tanti
- Inserm (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Unit 1065, Centre Méditerranéen de Médecine Moléculaire, Team 7 "Molecular and Cellular Physiopathology of Obesity and Diabetes," and Université Nice Sophia Antipolis (F.B., F.C., K.D., F.M., B.V., M.C., J.-F.T.), Centre Méditerranéen de Médecine Moléculaire, 06204 Cedex 3 Nice, France; and Instituto Investigaciones Biomédicas Alberto Sols (S.A.), Consejo Superior de Investigaciones Científicas-Universidad Autonoma de Madrid, 28029 Madrid, Spain
| |
Collapse
|
10
|
Regazzetti C, Dumas K, Lacas-Gervais S, Pastor F, Peraldi P, Bonnafous S, Dugail I, Le Lay S, Valet P, Le Marchand-Brustel Y, Tran A, Gual P, Tanti JF, Cormont M, Giorgetti-Peraldi S. Hypoxia inhibits Cavin-1 and Cavin-2 expression and down-regulates caveolae in adipocytes. Endocrinology 2015; 156:789-801. [PMID: 25521582 DOI: 10.1210/en.2014-1656] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
During obesity, a hypoxic state develops within the adipose tissue, resulting in insulin resistance. To understand the underlying mechanism, we analyzed the involvement of caveolae because they play a crucial role in the activation of insulin receptors. In the present study, we demonstrate that in 3T3-L1 adipocytes, hypoxia induces the disappearance of caveolae and inhibits the expression of Cavin-1 and Cavin-2, two proteins necessary for the formation of caveolae. In mice, hypoxia induced by the ligature of the spermatic artery results in the decrease of cavin-1 and cavin-2 expression in the epididymal adipose tissue. Down-regulation of the expression of cavins in response to hypoxia is dependent on hypoxia-inducible factor-1. Indeed, the inhibition of hypoxia-inducible factor-1 restores the expression of cavins and caveolae formation. Expression of cavins regulates insulin signaling because the silencing of cavin-1 and cavin-2 impairs insulin signaling pathway. In human, cavin-1 and cavin-2 are decreased in the sc adipose tissue of obese diabetic patients compared with lean subjects. Moreover, the expression of cavin-2 correlates negatively with the homeostatic model assessment index of insulin resistance and glycated hemoglobin level. In conclusion, we propose a new mechanism in which hypoxia inhibits cavin-1 and cavin-2 expression, resulting in the disappearance of caveolae. This leads to the inhibition of insulin signaling and the establishment of insulin resistance.
Collapse
Affiliation(s)
- Claire Regazzetti
- INSERM Unité 1065 (C.R., K.D., F.P., Y.L.M.-B., J.-F.T., M.C., S.G.-P.), C3M, Mediterranean Research Centre for Molecular Medicine, Team 7 (Cellular and Molecular Physiopathology of Obesity and Diabetes), Unité de Formation et de Recherche (UFR) Medicine (C.R., K.D., F.P., P.P., S.B., Y.L.M.-B., A.T., P.G., J.-F.T., M.C., S.G.-P.), and INSERM Unité 1065 (S.B., A.T., P.G.), C3M, Mediterranean Research Centre for Molecular Medicine, Team 8 (Hepatic Complications in Obesity),University of Nice, Sophia Antipolis F-06204 Nice, France; Centre Commun de Microscopie Appliquée (S.L.-G.), University of Nice, Sophia Antipolis, UFR Sciences, Parc Valrose, F-06108 Nice, France; Unité Mixte de Recherche Centre National de la Recherche Scientifique 7277 (P.P.), Unité Mixte de Recherche INSERM Unité 1091, UFR Medicine, F-06107 Nice, France; Centre Hospitalier Universitaire de Nice, Digestive Center (S.B., A.T.), Nice F-06202, Cedex 3, France; INSERM Unité Mixte de Recherche S872 (I.D.), Centre de Recherche des Cordeliers, Eq8, F-75006 Paris, France; INSERM Unité 1063 (S.L.L.), Stress Oxydant et Pathologies Métaboliques, Institut de Biologie en Santé, F-49933 Angers, France; and INSERM Unité Mixte de Recherche 1048 (P.V.), Institut des Maladies Métaboliques et Cardiovasculaires, Université Paul Sabatier, F-31432 Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ceppo F, Berthou F, Jager J, Dumas K, Cormont M, Tanti JF. Implication of the Tpl2 kinase in inflammatory changes and insulin resistance induced by the interaction between adipocytes and macrophages. Endocrinology 2014; 155:951-64. [PMID: 24424060 DOI: 10.1210/en.2013-1815] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Adipose tissue inflammation is associated with the development of insulin resistance. In obese adipose tissue, lipopolysaccharides (LPSs) and saturated fatty acids trigger inflammatory factors that mediate a paracrine loop between adipocytes and macrophages. However, the inflammatory signaling proteins underlying this cross talk remain to be identified. The mitogen-activated protein kinase kinase kinase tumor progression locus 2 (Tpl2) is activated by inflammatory stimuli, including LPS, and its expression is up-regulated in obese adipose tissue, but its role in the interaction between adipocytes and macrophages remains ill-defined. To assess the implication of Tpl2 in the cross talk between these 2 cell types, we used coculture system and conditioned medium (CM) from macrophages. Pharmacological inhibition of Tpl2 in the coculture markedly reduced lipolysis and cytokine production and prevented the decrease in adipocyte insulin signaling. Tpl2 knockdown in cocultured adipocytes reduced lipolysis but had a weak effect on cytokine production and did not prevent the alteration of insulin signaling. By contrast, Tpl2 silencing in cocultured macrophages resulted in a marked inhibition of cytokine production and prevented the alteration of adipocyte insulin signaling. Further, when Tpl2 was inhibited in LPS-activated macrophages, the produced CM did not alter adipocyte insulin signaling and did not induce an inflammatory response in adipocytes. By contrast, Tpl2 silencing in adipocytes did not prevent the deleterious effects of a CM from LPS-activated macrophages. Together, these data establish that Tpl2, mainly in macrophages, is involved in the cross talk between adipocytes and macrophages that promotes inflammatory changes and alteration of insulin signaling in adipocytes.
Collapse
Affiliation(s)
- Franck Ceppo
- INSERM Unité 1065/Centre Méditerranéen de Médecine Moléculaire (C3M) and Université de Nice Sophia Antipolis (F.C., F.B., J.J., K.D, M.C., J.-F.T.), F-06204, Nice, France
| | | | | | | | | | | |
Collapse
|
12
|
Regazzetti C, Dumas K, Le Marchand-Brustel Y, Peraldi P, Tanti JF, Giorgetti-Peraldi S. Regulated in development and DNA damage responses -1 (REDD1) protein contributes to insulin signaling pathway in adipocytes. PLoS One 2012; 7:e52154. [PMID: 23272222 PMCID: PMC3525563 DOI: 10.1371/journal.pone.0052154] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2012] [Accepted: 11/08/2012] [Indexed: 01/17/2023] Open
Abstract
REDD1 (Regulated in development and DNA damage response 1) is a hypoxia and stress response gene and is a negative regulator of mTORC1. Since mTORC1 is involved in the negative feedback loop of insulin signaling, we have studied the role of REDD1 on insulin signaling pathway and its regulation by insulin. In human and murine adipocytes, insulin transiently stimulates REDD1 expression through a MEK dependent pathway. In HEK-293 cells, expression of a constitutive active form of MEK stabilizes REDD1 and protects REDD1 from proteasomal degradation mediated by CUL4A-DDB1 ubiquitin ligase complex. In 3T3-L1 adipocytes, silencing of REDD1 with siRNA induces an increase of mTORC1 activity as well as an inhibition of insulin signaling pathway and lipogenesis. Rapamycin, a mTORC1 inhibitor, restores the insulin signaling after downregulation of REDD1 expression. This observation suggests that REDD1 positively regulates insulin signaling through the inhibition of mTORC1 activity. In conclusion, our results demonstrate that insulin increases REDD1 expression, and that REDD1 participates in the biological response to insulin.
Collapse
Affiliation(s)
- Claire Regazzetti
- INSERM U 1065, Mediterranean Research Centre for Molecular Medicine, Team: Cellular and Molecular Physiopathology of obesity and diabetes, Nice, France
- University of Nice Sophia Antipolis, UFR Medicine, Nice, France
| | - Karine Dumas
- INSERM U 1065, Mediterranean Research Centre for Molecular Medicine, Team: Cellular and Molecular Physiopathology of obesity and diabetes, Nice, France
- University of Nice Sophia Antipolis, UFR Medicine, Nice, France
| | - Yannick Le Marchand-Brustel
- INSERM U 1065, Mediterranean Research Centre for Molecular Medicine, Team: Cellular and Molecular Physiopathology of obesity and diabetes, Nice, France
- University of Nice Sophia Antipolis, UFR Medicine, Nice, France
| | - Pascal Peraldi
- University of Nice Sophia Antipolis, UFR Medicine, Nice, France
- UMR CNRS 7277, UMR INSERM 1091, Faculty of Medicine, Nice, France
| | - Jean-François Tanti
- INSERM U 1065, Mediterranean Research Centre for Molecular Medicine, Team: Cellular and Molecular Physiopathology of obesity and diabetes, Nice, France
- University of Nice Sophia Antipolis, UFR Medicine, Nice, France
| | - Sophie Giorgetti-Peraldi
- INSERM U 1065, Mediterranean Research Centre for Molecular Medicine, Team: Cellular and Molecular Physiopathology of obesity and diabetes, Nice, France
- University of Nice Sophia Antipolis, UFR Medicine, Nice, France
- * E-mail:
| |
Collapse
|
13
|
Greenway FL, Martin CK, Gupta AK, Cruickshank S, Whitehouse J, DeYoung L, Kamdar K, Caruso MK, Roberts AT, England M, Dumas K, Laidlaw BJF, Rogers B, Cowley MA. Using intranasal lidocaine to reduce food intake. Int J Obes (Lond) 2006; 31:858-63. [PMID: 17130849 DOI: 10.1038/sj.ijo.0803506] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Develop a dose-response curve for the effect of intranasal lidocaine on food intake. DESIGN Healthy obese subjects had food intake, ratings of hunger, desire to eat, craving and fullness measured at lunch after an overnight fast. Four treatments were given as nose drops (0.5-0.6 ml per nostril) 5 min before the meal in a double-blind manner with a four period crossover design including a 7-day washout between periods. The treatments were saline, 2.5, 10 and 25 mg lidocaine per nostril. The order of administration was randomly assigned to each subject. Electrocardiograms, vital signs, chemistry panels, complete blood counts (CBC) and nasal inspections were carried out before and after each dose. SUBJECTS Forty-seven subjects were screened, 34 were randomized and 20 subjects completed all four study periods in the trial. The subjects were 39+/-12.5 (s.d) years of age, had a weight of 91+/-13.0 kg, a height of 167+/-10.3 cm, 56% were women, 47% were African-American and 53% were Caucasian. MEASUREMENTS Food intake, rating of hunger, desire to eat, craving and fullness are measures of efficacy. Adverse events, electrocardiograms, vital signs, chemistry panels, nasal inspections, CBC and physical exams are measures of safety. RESULTS The mean reduction in food intake vs saline control in the 20 subjects completing all four study periods was 3.3+/-7% (s.d), 4.2+/-8.5% and 7.4+/-7.3% in the 2.5 mg, 10 and 25 mg per nostril groups, respectively (P=NS). Hunger and desire to eat in subjects who completed at least one study period decreased dose dependently (P<0.03, at the 25 mg per nostril dose). There were no clinically significant changes in safety measures, electrocardiograms, vital signs, chemistry panels, CBC or nasal inspections. CONCLUSION Intranasal lidocaine reduced hunger and the desire to eat, but this did not translate into a significant reduction in food intake suggesting that intranasal lidocaine will not have value in treating obesity.
Collapse
Affiliation(s)
- F L Greenway
- Outpatient Clinic Unit, Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Billotte WG, Dumas K, Hofmann MC. Transcriptional pathways induced by fluid shear stress in mouse preosteoblast cells. Biomed Sci Instrum 2001; 37:1-6. [PMID: 11347369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
Recent findings support the idea that fluid movement in the bone is a key factor in bone formation and related cellular responses. However, the precise molecular mechanisms are not known. Our data demonstrates that fluid shear stress is a key factor in the activation of specific transcriptional pathways in murine preosteoblast (MC3T3E1) cells. MC3T3E1 cells have increased expression of the egr-1 and p57kip2 genes after being subjected to 0.3 dynes/cm2 of fluid shear stress. The MC3T3E1 cells are already known to express egr-1, a multipotent transcription factor, after high levels of fluid shear stress, but this is the first demonstration of egr-1 expression after low levels of fluid shear stress. Moreover, this is the first study showing expression of p57kip2 by the MC3T3E1 cells after fluid shear stress. The expression of p57kip2, a cyclin dependent kinase inhibitor, is a strong indicator that the cells are exiting the cell cycle and are beginning to differentiate. Our data shows decreased 3H-thymidine incorporation up to 18 hours post stress, which agrees with the upregulation of p57kip2 as a result of fluid shear stress.
Collapse
Affiliation(s)
- W G Billotte
- Biology Department, University of Dayton, Dayton, OH 45469, USA
| | | | | |
Collapse
|
15
|
Varga-Weisz PD, Wilm M, Bonte E, Dumas K, Mann M, Becker PB. Chromatin-remodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 1997; 388:598-602. [PMID: 9252192 DOI: 10.1038/41587] [Citation(s) in RCA: 413] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Repressive chromatin structures need to be unravelled to allow DNA-binding proteins access to their target sequences. This de-repression constitutes an important point at which transcription and presumably other nuclear processes can be regulated. Energy-consuming enzyme complexes that facilitate the interaction of transcription factors with chromatin by modifying nucleosome structure are involved in this regulation. One such factor, nucleosome-remodelling factor (NURF), has been isolated from Drosophila embryo extracts. We have now identified a chromatin-accessibility complex (CHRAC) which uses energy to increase the general accessibility of DNA in chromatin. However, unlike other known chromatin remodelling factors, CHRAC can also function during chromatin assembly: it uses ATP to convert irregular chromatin into a regular array of nucleosomes with even spacing. CHRAC combines enzymes that modulate nucleosome structure and DNA topology. Using mass spectrometry, we identified two of the five CHRAC subunits as the ATPase ISWI, which is also part of NURF, and topoisomerase II. The presence of ISWI in different contexts suggests that chromatin remodelling machines have a modular nature and that ISWI has a central role in different chromatin remodelling reactions.
Collapse
|